Funder: METAvivor
Due Dates: March 11, 2025 (Letter of Intent) | August 19, 2025 (Internal Submission) | December 30, 2025 (Full Application)
Funding Amounts: Amount not specified; typically supports advanced translational or clinical research projects over 1–2 years.
Summary: Supports translational and clinical research with clear potential to improve outcomes for people living with metastatic breast cancer.
Key Information: Patient advocate involvement is required in both application preparation and research.